Trial Profile
Comparative Tolerability of Protease Inhibitors and the Associated Impact on Persistence, Healthcare Utilization, and Healthcare Costs.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Dec 2012
Price :
$35
*
At a glance
- Drugs Atazanavir (Primary) ; Darunavir (Primary) ; Fosamprenavir (Primary) ; Lopinavir (Primary)
- Indications HIV infections
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Dec 2011 Planned end date changed from 1 Nov 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.
- 14 Oct 2011 New trial record